

- The Anti-Retroviral Analysis by Monte Carlo Individual Simulation (ARAMIS) model was adapted to evaluate the cost-effectiveness of dolutegravir (DTG) in Canada in treatment-naïve (TN) and treatment-experienced (TE) HIV-1 patients
- DTG was compared to efavirenz, raltegravir (RAL), darunavir/ritonavir, rilpivirine, elvitegravir/cobicistat, atazanavir/ritonavir and lopinavir/ritonavir in TN patients and to RAL in TE patients
- DTG was found to be more effective and less costly in the management of both TN and TE patients infected with HIV when compared to the most widely used agents
- DTG fulfils a clinical need among patients infected with HIV across the whole spectrum of the disease by offering high-level efficacy combined with advantages in tolerability and a high barrier to resistance

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by ViiV Healthcare. Medical editing assistance for this study was provided by Chris Lawrence. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).